Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Early ctDNA dynamics as a surrogate for progression free survival in advanced breast cancer in the BEECH trial.

Hrebien S, Citi V, Garcia-Murillas I, Cutts R, Fenwick K, Kozarewa I, McEwen R, Ratnayake J, Maudsley R, Carr TH, de Bruin EC, Schiavon G, Oliveira M, Turner NC.

Ann Oncol. 2019 Mar 12. pii: mdz085. doi: 10.1093/annonc/mdz085. [Epub ahead of print]

2.

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.

Turner NC, Alarcón E, Armstrong AC, Philco M, López Chuken YA, Sablin MP, Tamura K, Gómez Villanueva A, Pérez-Fidalgo JA, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Foxley A, Lindemann JPO, Maudsley R, Moschetta M, Outhwaite E, Pass M, Rugman P, Schiavon G, Oliveira M.

Ann Oncol. 2019 May 1;30(5):774-780. doi: 10.1093/annonc/mdz086.

3.

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers.

Banerji U, Dean EJ, Pérez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose H, Barrett JC, Carr TH, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Elvin P, Foxley A, Lawrence P, Lindemann JPO, Maudsley R, Pass M, Rowlands V, Rugman P, Schiavon G, Yates J, Schellens JHM.

Clin Cancer Res. 2018 May 1;24(9):2050-2059. doi: 10.1158/1078-0432.CCR-17-2260. Epub 2017 Oct 24.

4.

Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patients.

de Bruin EC, Whiteley JL, Corcoran C, Kirk PM, Fox JC, Armisen J, Lindemann JPO, Schiavon G, Ambrose HJ, Kohlmann A.

PLoS One. 2017 May 4;12(5):e0175779. doi: 10.1371/journal.pone.0175779. eCollection 2017.

5.

Analysis of intratumor heterogeneity unravels lung cancer evolution.

de Bruin EC, McGranahan N, Swanton C.

Mol Cell Oncol. 2015 Apr 1;2(3):e985549. doi: 10.4161/23723556.2014.985549. eCollection 2015 Jul-Sep.

6.

Clonal status of actionable driver events and the timing of mutational processes in cancer evolution.

McGranahan N, Favero F, de Bruin EC, Birkbak NJ, Szallasi Z, Swanton C.

Sci Transl Med. 2015 Apr 15;7(283):283ra54. doi: 10.1126/scitranslmed.aaa1408.

7.

Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution.

Kovac M, Navas C, Horswell S, Salm M, Bardella C, Rowan A, Stares M, Castro-Giner F, Fisher R, de Bruin EC, Kovacova M, Gorman M, Makino S, Williams J, Jaeger E, Jones A, Howarth K, Larkin J, Pickering L, Gore M, Nicol DL, Hazell S, Stamp G, O'Brien T, Challacombe B, Matthews N, Phillimore B, Begum S, Rabinowitz A, Varela I, Chandra A, Horsfield C, Polson A, Tran M, Bhatt R, Terracciano L, Eppenberger-Castori S, Protheroe A, Maher E, El Bahrawy M, Fleming S, Ratcliffe P, Heinimann K, Swanton C, Tomlinson I.

Nat Commun. 2015 Mar 19;6:6336. doi: 10.1038/ncomms7336.

8.

Spatial and temporal diversity in genomic instability processes defines lung cancer evolution.

de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, Jamal-Hanjani M, Shafi S, Murugaesu N, Rowan AJ, Grönroos E, Muhammad MA, Horswell S, Gerlinger M, Varela I, Jones D, Marshall J, Voet T, Van Loo P, Rassl DM, Rintoul RC, Janes SM, Lee SM, Forster M, Ahmad T, Lawrence D, Falzon M, Capitanio A, Harkins TT, Lee CC, Tom W, Teefe E, Chen SC, Begum S, Rabinowitz A, Phillimore B, Spencer-Dene B, Stamp G, Szallasi Z, Matthews N, Stewart A, Campbell P, Swanton C.

Science. 2014 Oct 10;346(6206):251-6. doi: 10.1126/science.1253462.

9.

Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine.

Hiley C, de Bruin EC, McGranahan N, Swanton C.

Genome Biol. 2014 Aug 27;15(8):453. doi: 10.1186/s13059-014-0453-8. Review.

10.

Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution.

Fisher R, Horswell S, Rowan A, Salm MP, de Bruin EC, Gulati S, McGranahan N, Stares M, Gerlinger M, Varela I, Crockford A, Favero F, Quidville V, André F, Navas C, Grönroos E, Nicol D, Hazell S, Hrouda D, O'Brien T, Matthews N, Phillimore B, Begum S, Rabinowitz A, Biggs J, Bates PA, McDonald NQ, Stamp G, Spencer-Dene B, Hsieh JJ, Xu J, Pickering L, Gore M, Larkin J, Swanton C.

Genome Biol. 2014 Aug 27;15(8):433. doi: 10.1186/s13059-014-0433-z.

11.

Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.

de Bruin EC, Cowell C, Warne PH, Jiang M, Saunders RE, Melnick MA, Gettinger S, Walther Z, Wurtz A, Heynen GJ, Heideman DA, Gómez-Román J, García-Castaño A, Gong Y, Ladanyi M, Varmus H, Bernards R, Smit EF, Politi K, Downward J.

Cancer Discov. 2014 May;4(5):606-19. doi: 10.1158/2159-8290.CD-13-0741. Epub 2014 Feb 17.

12.

Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications.

de Bruin EC, Taylor TB, Swanton C.

Genome Med. 2013 Nov 22;5(11):101. doi: 10.1186/gm505. eCollection 2013. Review.

13.

Apoptosis and non-apoptotic deaths in cancer development and treatment response.

de Bruin EC, Medema JP.

Cancer Treat Rev. 2008 Dec;34(8):737-49. doi: 10.1016/j.ctrv.2008.07.001. Epub 2008 Aug 22. Review.

PMID:
18722718
14.

Epithelial human leukocyte antigen-DR expression predicts reduced recurrence rates and prolonged survival in rectal cancer patients.

de Bruin EC, van de Velde CJ, van Krieken JH, Marijnen CA, Medema JP.

Clin Cancer Res. 2008 Feb 15;14(4):1073-9. doi: 10.1158/1078-0432.CCR-07-1597.

15.

Caspase-3 activity predicts local recurrence in rectal cancer.

de Heer P, de Bruin EC, Klein-Kranenbarg E, Aalbers RI, Marijnen CA, Putter H, de Bont HJ, Nagelkerke JF, van Krieken JH, Verspaget HW, van de Velde CJ, Kuppen PJ; Dutch Colorectal Cancer Group.

Clin Cancer Res. 2007 Oct 1;13(19):5810-5.

16.

Clinical impact of HLA class I expression in rectal cancer.

Speetjens FM, de Bruin EC, Morreau H, Zeestraten EC, Putter H, van Krieken JH, van Buren MM, van Velzen M, Dekker-Ensink NG, van de Velde CJ, Kuppen PJ.

Cancer Immunol Immunother. 2008 May;57(5):601-9. Epub 2007 Sep 15.

17.

Gene expression profiling reveals two separate mechanisms regulating apoptosis in rectal carcinomas in vivo.

de Bruin EC, van de Pas S, van de Velde CJ, van Krieken JH, Peltenburg LT, Marijnen CA, Medema JP.

Apoptosis. 2007 Sep;12(9):1671-80.

18.

Cyclooxygenase 2 expression in rectal cancer is of prognostic significance in patients receiving preoperative radiotherapy.

de Heer P, Gosens MJ, de Bruin EC, Dekker-Ensink NG, Putter H, Marijnen CA, van den Brule AJ, van Krieken JH, Rutten HJ, Kuppen PJ, van de Velde CJ; Dutch Colorectal Cancer Group.

Clin Cancer Res. 2007 May 15;13(10):2955-60.

19.

Prognostic value of apoptosis in rectal cancer patients of the dutch total mesorectal excision trial: radiotherapy is redundant in intrinsically high-apoptotic tumors.

de Bruin EC, van de Velde CJ, van de Pas S, Nagtegaal ID, van Krieken JH, Gosens MJ, Peltenburg LT, Medema JP, Marijnen CA.

Clin Cancer Res. 2006 Nov 1;12(21):6432-6.

20.

Production, purification and characterisation of recombinant Fahsin, a novel antistasin-type proteinase inhibitor.

de Bruin EC, Roem D, Bulder I, Dieker M, Voerman G, Hack CE.

FEMS Yeast Res. 2005 Nov;5(11):1069-77.

21.

Macrodissection versus microdissection of rectal carcinoma: minor influence of stroma cells to tumor cell gene expression profiles.

de Bruin EC, van de Pas S, Lips EH, van Eijk R, van der Zee MM, Lombaerts M, van Wezel T, Marijnen CA, van Krieken JH, Medema JP, van de Velde CJ, Eilers PH, Peltenburg LT.

BMC Genomics. 2005 Oct 14;6:142.

22.

Pharmaceutical proteins from methylotrophic yeasts.

de Bruin EC, Duitman EH, de Boer AL, Veenhuis M, Bos IG, Hack CE.

Methods Mol Biol. 2005;308:65-76. No abstract available.

PMID:
16082026
23.

Expression and function of the apoptosis effector Apaf-1 in melanoma.

Peltenburg LT, de Bruin EC, Meersma D, Smit NP, Schrier PI, Medema JP.

Cell Death Differ. 2005 Jun;12(6):678-9. No abstract available.

24.

c-Myc is able to sensitize human melanoma cells to diverse apoptotic triggers.

Peltenburg LT, de Bruin EC, Meersma D, Wilting S, Jürgensmeier JM, Schrier PI.

Melanoma Res. 2004 Feb;14(1):3-12.

PMID:
15091188
25.

A serine protease is involved in the initiation of DNA damage-induced apoptosis.

de Bruin EC, Meersma D, de Wilde J, den Otter I, Schipper EM, Medema JP, Peltenburg LT.

Cell Death Differ. 2003 Oct;10(10):1204-12.

26.

Recombinant human C1-inhibitor produced in Pichia pastoris has the same inhibitory capacity as plasma C1-inhibitor.

Bos IG, de Bruin EC, Karuntu YA, Modderman PW, Eldering E, Hack CE.

Biochim Biophys Acta. 2003 May 30;1648(1-2):75-83.

PMID:
12758149
27.
28.

Secreted production of a custom-designed, highly hydrophilic gelatin in Pichia pastoris.

Werten MW, Wisselink WH, Jansen-van den Bosch TJ, de Bruin EC, de Wolf FA.

Protein Eng. 2001 Jun;14(6):447-54.

PMID:
11477225
29.

Expression and secretion of human alpha1(I) procollagen fragment by Hansenula polymorpha as compared to Pichia pastoris.

de Bruin EC, de Wolf FA, Laane NC.

Enzyme Microb Technol. 2000 Jun 1;26(9-10):640-644.

PMID:
10862867

Supplemental Content

Loading ...
Support Center